Garheng Kong

CIK: 0001435183

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (33.3%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

XERS

Xeris Biopharma Holdings, Inc.

Director

LABCORP HOLDINGS INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2026
Award(A)
Direct
24.2K shares-
LH
LABCORP HOLDINGS INC.
Feb 11, 2026
Exercise(M)
Direct
897 shares-
LH
LABCORP HOLDINGS INC.
Feb 10, 2026
Award(A)
Restricted Stock Unit
Direct
773 shares-
XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2025
Award(A)
Direct
50K shares-
LH
LABCORP HOLDINGS INC.
Feb 11, 2025
Award(A)
Restricted Stock Unit
Direct
897 shares-
LH
LABCORP HOLDINGS INC.
Feb 6, 2025
Exercise(M)
Direct
944 shares-

		Type	Shares	Price		Ownership
Jun 4, 2026	XERS Xeris Biopharma Holdings, Inc.	Award(A)	24,193	-	$0	Direct
Feb 11, 2026	LH LABCORP HOLDINGS INC.	Exercise(M)	897	-	$0	Direct
Feb 10, 2026	LH LABCORP HOLDINGS INC.	Award(A) Restricted Stock Unit	773	-	-	Direct
Jun 4, 2025	XERS Xeris Biopharma Holdings, Inc.	Award(A)	50,000	-	-	Direct
Feb 11, 2025	LH LABCORP HOLDINGS INC.	Award(A) Restricted Stock Unit	897	-	-	Direct
Feb 6, 2025	LH LABCORP HOLDINGS INC.	Exercise(M)	944	-	-	Direct

1-6 of 6 transactions

About Kong Garheng

Kong Garheng (SEC CIK 0001435183) files insider reports with the SEC as Director of Xeris Biopharma Holdings, Inc. (XERS) and Director of LABCORP HOLDINGS INC. (LH).

Signal8 holds 6 ownership filings by Kong Garheng, all Form 4s, filed between Feb 10, 2025 and Jun 5, 2026. Those filings report 6 transactions, from Feb 6, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kong Garheng's filings is in CHICAGO, IL.

Recent filings by Kong Garheng

Jun 4, 2026: Grant or award of XERS shares (Form 4, code A).
Feb 11, 2026: Option exercise of LH shares (Form 4, code M).
Feb 10, 2026: Grant or award of LH derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of XERS shares (Form 4, code A).
Feb 11, 2025: Grant or award of LH derivative securities (Form 4, code A).

Other insiders filing for Xeris Biopharma Holdings, Inc. (XERS)

How to read Form 4 transaction codes